The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
artemisinin results in increased activity of NR1I3 protein; artemisinin results in increased activity of NR1I3 protein alternative form; artemisinin results in increased activity of NR1I3 protein mutant form androstan-3-ol inhibits the reaction [artemisinin results in increased activity of NR1I3 protein mutant form]; artemisinin inhibits the reaction [androstan-3-ol results in decreased activity of NR1I3 protein alternative form]; artemisinin inhibits the reaction [Imidazoles results in decreased activity of NR1I3 protein alternative form]; Imidazoles inhibits the reaction [artemisinin results in increased activity of NR1I3 protein mutant form]
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP]
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin]; [Verapamil results in decreased activity of ABCB1 protein] which affects the transport of Digoxin; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of TTR mRNA]; MYL9 protein modified form affects the reaction [ABCB1 protein affects the transport of Digoxin analog] ABCB1 gene mutant form results in increased susceptibility to Digoxin; ABCB1 mutant form results in increased susceptibility to Digoxin
[INS protein co-treated with Glucose] results in increased susceptibility to Digoxin; [INS protein co-treated with Glucose] results in increased uptake of Digoxin
ABCB1 gene mutant form results in increased susceptibility to doramectin; ABCB1 mutant form results in increased susceptibility to doramectin ABCB1 gene mutant form affects the reaction [doramectin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of TTR mRNA]
ABCB1 protein affects the abundance of Ivermectin ABCB1 gene mutant form results in increased susceptibility to Ivermectin; ABCB1 mutant form results in increased susceptibility to Ivermectin; ABCB1 protein mutant form results in increased susceptibility to Ivermectin ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of TTR mRNA]
Ketoconazole results in decreased expression of ABCB1 mRNA [Ketoconazole results in decreased activity of ABCB1 protein] which results in decreased transport of Technetium Tc 99m Sestamibi
Ketoconazole inhibits the reaction [CYP3A12 protein results in increased hydroxylation of Diazepam] Ketoconazole results in decreased activity of CYP3A12 protein
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL17 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL2 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of IL31RA promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of TSLP promoter
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKCZ protein]
ABCB1 gene mutant form results in increased susceptibility to moxidectin; ABCB1 mutant form results in increased susceptibility to moxidectin ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of TTR mRNA]
Monensin affects the localization of SLC6A9 protein Tetradecanoylphorbol Acetate promotes the reaction [Monensin affects the localization of SLC6A9 protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein] ochratoxin A results in increased expression of ACTA2 mRNA; ochratoxin A results in increased expression of ACTA2 protein
ochratoxin A results in increased expression of TGFB1 mRNA; ochratoxin A results in increased expression of TGFB1 protein CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein] ochratoxin A results in increased expression of GSDMD mRNA; ochratoxin A results in increased expression of GSDMD protein
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein] ochratoxin A results in increased expression of IL1B mRNA; ochratoxin A results in increased expression of IL1B protein
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of NLRP3 mRNA; ochratoxin A results in increased expression of NLRP3 protein
ochratoxin A results in increased expression of PYCARD mRNA; ochratoxin A results in increased expression of PYCARD protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of VIM protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of VIM mRNA; ochratoxin A results in increased expression of VIM protein
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid; [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP]
browse the term
